EP0407399A4 - Immunosupression with anti-pan t-cell immunotoxin compositions - Google Patents
Immunosupression with anti-pan t-cell immunotoxin compositionsInfo
- Publication number
- EP0407399A4 EP0407399A4 EP19890902585 EP89902585A EP0407399A4 EP 0407399 A4 EP0407399 A4 EP 0407399A4 EP 19890902585 EP19890902585 EP 19890902585 EP 89902585 A EP89902585 A EP 89902585A EP 0407399 A4 EP0407399 A4 EP 0407399A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- immunosupression
- pan
- cell immunotoxin
- immunotoxin compositions
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A61K47/6827—Ricin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US151741 | 1980-05-20 | ||
| US15174188A | 1988-02-03 | 1988-02-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0407399A1 EP0407399A1 (fr) | 1991-01-16 |
| EP0407399A4 true EP0407399A4 (en) | 1991-06-19 |
Family
ID=22540067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19890902585 Withdrawn EP0407399A4 (en) | 1988-02-03 | 1989-02-03 | Immunosupression with anti-pan t-cell immunotoxin compositions |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0407399A4 (fr) |
| JP (1) | JPH03503164A (fr) |
| WO (1) | WO1989006967A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0397798A4 (en) * | 1988-02-03 | 1991-10-30 | Xoma Corporation | Therapeutic use of anti-t cell immunotoxin for autoimmune diseases |
| FI914160A7 (fi) * | 1989-03-06 | 1991-09-03 | Univ California | Autoimmuunisten tautien analysointi ja hoito |
| US5397702A (en) * | 1989-03-06 | 1995-03-14 | The Regents Of The University Of California | Assay for and treatment of autoimmune diseases |
| IL98932A0 (en) * | 1990-07-27 | 1992-07-15 | Univ California | Assay,kits and methods based on nk+channel expression |
| IT1249051B (it) * | 1991-02-26 | 1995-02-11 | Italfarmaco Spa | Immunotossina da anticorpi monoclonali anti-cd5 |
| US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US6146850A (en) * | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
| ATE249840T1 (de) * | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| GB9217124D0 (en) * | 1992-08-13 | 1992-09-23 | Antisoma Ltd | Medical treatment |
| US5759546A (en) * | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| EP0945139A1 (fr) * | 1998-03-23 | 1999-09-29 | Katholieke Universiteit Nijmegen | Méthode et moyens de traitement de maladies immunologiques telle que la maladie des greffes vis-à-vis de l'hÔte |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
| US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
| US4731244A (en) * | 1985-11-13 | 1988-03-15 | Ortho Pharmaceutical Corporation | Monoclonal antibody therapy |
-
1989
- 1989-02-03 WO PCT/US1989/000439 patent/WO1989006967A1/fr not_active Ceased
- 1989-02-03 EP EP19890902585 patent/EP0407399A4/en not_active Withdrawn
- 1989-02-03 JP JP1502401A patent/JPH03503164A/ja active Pending
Non-Patent Citations (2)
| Title |
|---|
| No further relevant documents have been disclosed. * |
| See also references of WO8906967A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03503164A (ja) | 1991-07-18 |
| WO1989006967A1 (fr) | 1989-08-10 |
| EP0407399A1 (fr) | 1991-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR890100636A (en) | Analgesic compositions | |
| GB2217229B (en) | Solubilising composition | |
| IL92230A0 (en) | Antibody-drug conjugates | |
| EP0407399A4 (en) | Immunosupression with anti-pan t-cell immunotoxin compositions | |
| GB8801756D0 (en) | Copolymer composition | |
| ZA919836B (en) | Gasoline composition | |
| GB8827697D0 (en) | Fabric-treatment composition | |
| US4962144B1 (en) | Composition | |
| GB2251493B (en) | Engaging lever arrangement | |
| ZA89524B (en) | Antibody conjugates | |
| GB8827698D0 (en) | Fabric-treatment composition | |
| GB8925535D0 (en) | Gasoline composition | |
| ZA891031B (en) | Compositions with enhanced penetration | |
| GB8822967D0 (en) | Moss-killing composition | |
| GR890100837A (en) | Herbicidac composition | |
| IE883489L (en) | Drug-monoclonalantibody conjugates | |
| SG177594G (en) | Gasoline composition | |
| GB8803035D0 (en) | Copolymer composition | |
| GB8801995D0 (en) | Copolymer composition | |
| PL276880A1 (en) | Antielectrostatic epoxyd composition | |
| RO101699B1 (en) | Polyolefines composition | |
| IL92875A0 (en) | Iminothiolanes and immunotoxin compositions comprising them | |
| CS8801053A2 (en) | Glow-starter with two bi-metals | |
| IE841526L (en) | Immunotoxin conjugates | |
| GB8800647D0 (en) | Composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19900723 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19910426 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19920304 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19920715 |